Shelter Pharma
43.60
-40.80(-100.00%)
Market Cap₹66.60 Cr
PE Ratio9.21
IndustryHealthcare
Company Performance:
1D-100.00%
1M-100.00%
6M-100.00%
1Y-100.00%
5Y-100.00%
View Company Insightsright
More news about Shelter Pharma
15Nov 25
Shelter Pharma Converts 7.35 Lakh Warrants to Equity Shares, Raising Rs. 2.33 Crore
Shelter Pharma Limited has converted 7,35,000 convertible equity warrants into equity shares at Rs. 31.75 per share, raising Rs. 2.33 crore from three non-promoter investors. This conversion increases the company's paid-up share capital from Rs. 14.86 crore to Rs. 15.60 crore, with the total number of equity shares rising from 1,48,62,792 to 1,55,97,792. The newly allotted shares will rank pari-passu with existing equity shares, and the company plans to apply for listing and trading approval on the stock exchange.
 no imag found
10Nov 25
Shelter Pharma Reports No Deviation in Rs. 9.30 Crore Warrant Proceeds Utilization
Shelter Pharma Limited has verified that the Rs. 9.30 crore raised from its recent preferential issue of warrants has been utilized as planned. The entire amount of Rs. 930.35 lakhs has been used for working capital requirements. The company issued 88,08,000 warrants at Rs. 42.25 each on August 6, 2025, receiving 25% of the subscription amount upfront. The remaining 75% is expected within 18 months. For the half-year ended September 30, 2025, Shelter Pharma reported revenue of Rs. 3,329.29 lakhs and a profit after tax of Rs. 450.07 lakhs, showing improved financial performance.
 no imag found
10Nov 25
Shelter Pharma Reports Rs 601.45 Crore Profit Before Tax in Half-Year Results
Shelter Pharma Limited announced unaudited financial results for H1 2025-26. Revenue decreased by 12.4% to Rs 2,329.29 crore, and profit before tax fell 37.8% to Rs 601.45 crore. However, basic EPS improved by 27.1% to Rs 3.89. Total assets increased to Rs 6,689.54 crore, and reserves grew to Rs 3,561.47 crore. The company received Rs 1,350.84 crore against share warrants and fully utilized Rs 930.35 crore from a preferential issue for working capital. Cash and cash equivalents rose to Rs 527.96 crore, strengthening liquidity.
 no imag found
06Nov 25
Shelter Pharma Secures ₹27,540 Order from Sudan Partner for D3 Cure Capsules
Shelter Pharma Limited announced securing another international order worth ₹27,540 from Sudan-based Taha Drugs & Chemicals Co. Ltd for D3 Cure Capsules. This represents the third order from the same client, following previous orders worth ₹98,875 and ₹27,600, demonstrating continued business expansion in international markets with execution timeline of 2 months.
 no imag found
22Sept 25
Shelter Pharma Installs 15 KW Solar Power Plant at Gujarat Factory, Embracing Sustainability
Shelter Pharma Limited has installed a 15 KW solar power plant on the roof of its factory in Himmatnagar, Gujarat. The installation is expected to have a 25-year lifespan, with cost recovery projected within 4 years and electricity cost savings anticipated for the subsequent 21 years. This move aligns with the company's commitment to sustainable manufacturing and eco-friendly practices.
 no imag found
08Aug 25
Shelter Pharma's 14 Veterinary Products Selected for Supply to AMUL
Shelter Pharma Limited announced that 14 of its veterinary products have been chosen for supply to Gujarat Co-operative Milk Marketing Federation Ltd. (AMUL). This selection marks a significant advancement for Shelter Pharma in the animal healthcare sector, particularly in the dairy industry. The company's management anticipates this partnership with AMUL to positively impact their business prospects in the animal healthcare segment. The selection also highlights Shelter Pharma's commitment to providing high-quality Ayurvedic welfare solutions for animals.
 no imag found
06Aug 25
Shelter Pharma Allots 88.08 Lakh Convertible Warrants Worth Rs 37.21 Crore
Shelter Pharma's Board of Directors has approved the allotment of 88,08,000 convertible share warrants at Rs 42.25 per warrant, raising Rs 37.21 crore. The warrants are issued to both promoter and non-promoter investors, with 34.09% allocated to the promoter group and 65.91% to non-promoters. The company has received an upfront payment of Rs 9.30 crore, with the remaining amount due upon conversion within 18 months. Notable allottees include Zubedabibi Nisarahmed Sabugar from the promoter group and Managing Director Mustaqim Nisarahmed Sabugar.
 no imag found
24Jul 25
Shelter Pharma Shareholders Unanimously Approve ₹38.46 Crore Warrant Issuance
Shelter Pharma Limited received unanimous shareholder approval for issuing up to 91.02 lakh convertible equity share warrants at ₹42.25 each, potentially raising ₹38.46 crore. The decision was made during an EGM on July 23, 2025, with 54.97% of total shares represented in voting. The warrants, convertible into one equity share each, will be issued to promoter and non-promoter investors via private placement. This capital raise aligns with the company's growth strategies in the pharmaceutical sector.
 no imag found
23Jul 25
Shelter Pharma Approves ₹38.46 Crore Warrant Issue in EGM
Shelter Pharma Limited held an EGM on July 23, 2025, to approve the issuance of up to 91,02,000 Convertible Equity Share Warrants at ₹42.25 per warrant. The total value of the issue could reach ₹38,45,59,500. The warrants, convertible into one equity share each, will be issued to both Promoter Group and Non-Promoters on a private placement and preferential basis. The company's Managing Director, Mr. Mustaqim Nisarahmed Sabugar, stated that the funds would support future prospects. Voting results are expected within 48 hours of the meeting's conclusion.
 no imag found
Shelter Pharma
43.60
-40.80
(-100.00%)
1 Year Returns:-100.00%
Industry Peers
Sun Pharmaceutical
1,621.50
(+0.71%)
Divis Laboratories
5,938.00
(-1.95%)
Torrent Pharmaceuticals
3,949.80
(-1.18%)
Cipla
1,299.50
(-2.21%)
Dr Reddys Laboratories
1,177.90
(-0.07%)
Lupin
2,102.00
(-1.55%)
Zydus Life Science
871.75
(-0.72%)
Mankind Pharma
2,057.80
(-1.72%)
Aurobindo Pharma
1,163.60
(-0.73%)
Alkem Laboratories
5,447.00
(-2.12%)